Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT07748169
Starting soon Observational

An Observational Study of Patients With Dermatologic Disease

NCT07748169 · tracked via the Priya Life Science USA tracker
Sponsor
Target PharmaSolutions, Inc
Phase
Observational
Started
2026-09
Last updated
2026-09-10

Condition(s) studied

VitiligoAtopic DermatitisAlopecia AreataHidradenitis Suppurativa (HS)

Study summary

TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual clinical practice in the United States and addresses important clinical questions regarding the management of DD by collecting and analyzing data from patients at academic medical centers and community medical practices and/or data from providers who treat them.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult or pediatric participants managed for DD invited to participate OR a provider who treats patients with these conditions. Informed consent is required for all Engaged Cohort participants. * Adult or pediatric participants at the time of enrollment with a diagnosis of DD by ICD code or other relevant healthcare code as part of the EHR interface. Exclusion Criteria: * Participant withdrew consent; Failure to complete activities as required per the cohort clarification letter.

Primary outcome measure(s)

  • To assess safety and effectiveness of DD treatments and treatments for complications of any dermatologic disease — 15 years
    The study will evaluate the characteristics of patients receiving various treatments, effectiveness of treatment, and medical events that develop while receiving treatment for DD
  • To characterize the natural history of disease in patients with dermatologic disease from various etiologies — 15 years
    A detailed analysis of available demographics (age, race, sex, country of birth, insurance status), medications, co-morbidities, and medical history from sites across the US will inform the profile for this patient population.
  • To establish learning health networks focused on quality of care for patients — 15 years
    Identify deficiencies and best practices in care of patients with DD. • Evaluate outcomes from targeted learning content in the management of patients with DD.

Trial sites (1)

FacilityCityRegionStatus
Greenwich Village Dermatology New York New York

More Target PharmaSolutions, Inc. trials in the USA

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC Active, not recruiting
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease Active, not recruiting
An Observational Study of Patients With Chronic Liver Disease Enrolling by invitation
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC Active, not recruiting
An Observational Study of Patients With Chronic Gastrointestinal Disease Active, not recruiting

Other trials for the same condition

A Study Evaluating APG777 in Atopic Dermatitis Active, not recruiting
A Study of Barzolvolimab in Patients With Atopic Dermatitis Active, not recruiting
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis Active, not recruiting
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients Recruiting
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07748169 on ClinicalTrials.gov ↗ ← All trials in the USA